People

Erika E. Forbes, PhD

Positions

Professor of Psychiatry, Psychology, Pediatrics, and Clinical and Translational Science, Western Psychiatric Institute and Clinic, University of Pittsburgh School of Medicine, Pittsburgh, PA

Education & Training

PhD, 2003, University of Pittsburgh, Psychology

Dr. Forbes' research addresses the regulation and dysregulation of positive affect and the processing of reward in childhood depression. Her current project involves a study of low activation of in reward-related brain areas, low subjective experience of positive affect in natural settings as measured by ecological momentary assessment, and the relationship of the fMRI-revealed brain activation to seeking and experiencing positive affects in natural settings.

David J. Kupfer, MD

Positions

Thomas Detre Professor, Department of Psychiatry, University of Pittsburgh School of Medicine and Western Psychiatric Institute and Clinic
Professor of Neuroscience and Clinical and Translational Science, University of Pittsburgh School of Medicine

Education & Training

MD, 1965, Yale University, Medicine

David J. Kupfer, MD, Distinguished Professor Emeritus, Department of Psychiatry, University of Pittsburgh School of Medicine, received his bachlor's and MD degress from Yale University. Following completion of an internship, Dr. Kupfer continued his postrgraduate clinical and resarch training at the Yale New Haven Hospital and the National Institute of Mental Health (NIMH).

In 1970, he was appointed Assistant Professor of Psychiatry at yale University School of Medicine. Dr. Kupfer joined the faculty at the University of Pittsburgh in 1973. From 1983 and 2009, Dr. Kupfer served as Chair of the Department of Psychiatry at the University of Pittsburgh School of Medicine, and Director of Research at Western Psychiatric Institute and Clinic. Under Dr. Kupfer's direction, WPIC became one of the nation's preeminent university-based psychiatric research centers. A prolific writer, Dr. Kupfer has authored and co-authored a combination of more than 1,000 articles, books, and book chapters. Dr. Kupfer's own research focused primarily on long-term treatment strategies for recurrent mood disorders including both psychotherapeutic and pharmacologic treatments, the pathogenesis of depression, and the relationship between biomarkers and depression. He is internationally recognized for his role as Chair of the American Psychiatric Association Task Force for DSM-5. In recognition of his contributions to the field, Dr. Kupfer has been the recipient of numerous awards and honors including his 1990 election to the National Academy of Medicine.

Alan F. Schatzberg, MD

Positions

Kenneth T. Norris, Jr., Professor, Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Stanford, CA

Education & Training

MD, 1968, New York University School of Medicine, Medicine

Dr. Schatzberg's research examines the biology and psychopharmacology of depressive disorders. Past studies include norepinephrine systems in depression as a means of subtyping, the biology of delusions in major depression, the clinical pharmacology of nondelusional depression with a focus on chronic depression, and the pharmacogenetics of antidepressant response. He was elected into the Institute of Medicine of the National Academy of Sciences in 2003, and he holds or has held co-editor, editorial board, or presidential positions with several journals and societies. From 1991 to 2010, he was the Chair of Psychiatry and Behavioral Sciences at Stanford University.

Rebecca Ashare, PhD

Position

Assistant Professor of Psychology

Education & Training

B.A. (Psychology) State University of New York at Buffalo, 2003
M.A. (Clinical Psychology) State University of New York at Buffalo, 2007
Ph.D. (Clinical Psychology) State University of New York at Buffalo

Dr. Ashare is an Associate Professor in the Department of Psychology in the College of arts and Sciences at the University at Buffalo, SUNY. She received her Ph.D. in Clinical Psychology at the State University of New York at Buffalo and completed her predoctoral clinical fellowship at the Yale University School of Medicine Division of Substance Abuse. She joined the Center for Interdisciplinary Research on Nicotine Addiction (CIRNA) at UPenn as a postdoctoral fellow and was appointed to faculty in 2012. At CIRNA, she continued her research identifying novel therapeutic targets that underlie smoking relapse and evaluating novel treatments to improve abstinence rates, with a particular focus on neurocognition.

Dr. Ashare’s research takes an interdisciplinary approach to understanding substance use among individuals with medical and psychiatric comorbidities. Most recently, this work has focused on three areas: (1) the mechanisms and outcomes of tobacco use among people with HIV (PWH); (2) digital interventions for smoking cessation among individuals with serious mental illness; and (3) the intersection of cannabis and opioid use for symptom management.

Her work in tobacco use and HIV evaluates the mechanisms and outcomes of tobacco use among PWH, a population with disproportionately high smoking rates. Coupled with the widespread use of antiretroviral therapy, PWH actually lose more life years to tobacco use than to HIV. Her research projects seek to understand: (1) the mechanisms that underlie high smoking rates; (2) why existing treatments are less effective and relapse rates are higher among PWH; and (3) how HIV and smoking my act synergistically and ultimately lead to worse clinical outcomes including cancer and impaired immune function.

She is also collaborating with investigators at Duke University on a multi-site clinical trial to evaluate the effectiveness of a mobile health application (i.e., smartphone app) for smoking cessation among individuals with serious mental illness. They are collaborating with outpatient psychiatry clinics at Erie County medical Center on this trial.

Dr. Ashare and her collaborators at Duke University also recently began a study to better understand cannabis use in the context of cancer. Specifically, they are studying whether cannabis may help to reduce opioid use for managing pain among cancer patients. This study is a collaboration with Roswell Park Cancer Institute, the University of Pennsylvania and Sidney Kimmel Cancer Center.

Melissa Brotman, PhD

Positions

Principal Investigator, Neuroscience and Novel Therapeutics Unit (NNT), Emotion and Development Branch, NIMH Intramural Research program

Melissa A. Brotman, Ph.D., is the principal investigator of the Neuroscience and Novel Therapeutics Unit (NNT) in the Emotion and Development Branch at the National Institute of Mental Health (NIMH) Intramural Research Program (IRP). Dr. Brotman received her Ph.D. in clinical psychology from the University of Pennsylvania, where she specialized in cognitive behavioral therapy for mood and anxiety disorders. After completing her clinical internship at the Veterans Affairs Maryland Health Care System/University of Maryland-Baltimore, she completed post-doctoral training in neuroscience, focusing on functional magnetic resonance imaging (fMRI) and clinical phenotyping of severe irritability in youth. Currently, her neurodevelopmental, translational research integrates basic and clinical approaches to the study of mood disorders in children and adolescents. Specifically, she uses affective neuroscience techniques to understand the brain-based mechanisms underlying severe irritability in youth and leverages pathophysiological knowledge to guide the development of novel targeted interventions.Dr. Brotman is Principal Investigator on NIMH protocol 15-M-0182 examining two novel, mechanism-based treatments for severe irritability in youth: (1) a computer-based treatment, interpretation bias training (IBT) that targets face emotion processing; and (2) an exposure-based cognitive-behavioral research therapy. Recruitment for both studies is ongoing.

Dr. Brotman is a Member of the American College of Neuropsychopharmacology (ACNP) and Chair of the ACNP Membership Advisory Task Force. She has received multiple research awards, including the NIMH IRP Seymour S. Kety Memorial Training Award, Society of Biological Psychiatry Travel Award, ACNP Young Investigator Memorial Travel Award, and Career Development Institute Award. She was awarded a 2018 NIH Bench-to-Bedside grant, is a consultant on numerous extramural grants, and is on the Editorial Board of the Journal of Affective Disorders and PLOS ONE. Finally, mentoring is a focal aspect of her career, and her mentorship was recently recognized through the NIMH Outstanding Mentor Award.

Enrico Castillo, MD, MSHPM

Positions

Associate Professor of Clinical Psychiatry, University of California, Los Angeles
Associate Vice Chair for Justice, Equity, Diversity, and Inclusion, UCLA Department of Psychiatry
Core Faculty, UCLA Center for Social Medicine
Affiliated Faculty, California Policy lab at UCLA
Affiliated Faculty, UCLA Center for Community Engagement

Education & Training

BA, University of Virginia (2005)
MD, University of Pittsburgh (2010)
Residency and Public Psychiatry Fellowship: Columbia University (2014, 2015)
MS Health Policy and Management: University of California, Los Angeles (2016)
Post-doctoral Research Fellowship: Robert Wood Johnson Foundation Clinical Scholars Program at UCLA (2017)

Dr. Enrico Castillo is an academic community psychiatrist, health services researcher, and medical educator in the UCLA Center for Social Medicine and the Associate Vice Chair for Justice, Equity, Diversity, and Inclusion in the UCLA Department of Psychiatry. His program of research focuses on enhancing the capacity of public systems to address health inequities through community-government-academic partnerships. In the roles of PI or Co-PI, he has secured over $1.9 million in research funding, and he has served on NIH and Department of Veterans Affairs scientific review committees. His research and educational work have been conducted in partnership with local, state, and national agencies and community organizations. He led a NIMH K23 project on the jail-to-homelessness pipeline experienced by individuals with serious mental illness. He serves in several national leadership roles in research and medical education, including the Mental Health Advisory Board of the Association of American Medical Colleges, and multiple positions in the American Psychiatric Association. He was one of three physician members of the second cohort of the New Voices Program of the National Academies of Sciences, Engineering, and Medicine. He is a member of the California State Council on Criminal Justice and Behavioral Health.

Jay Fournier, PhD

Positions

Director, Mood and Anxiety Program
Co-Director, Division of Cognition and Emotion
Associate Professor, Department of Psychiatry & Behavioral Health

Education & Training

PhD, University of Pennsylvania

Dr. Fournier is an associate professor in the Department of Psychiatry at the Ohio State University School of Medicine. He is a practicing clinical psychologist with an active research program in the cognitive affective neuroscience of personality and depression.

Dr. Fournier completed his undergraduate education in psychology and philosophy at Brandeis University, he earned his PhD in clinical psychology from the University of Pennsylvania, and he completed his clinical psychology internship at Western Psychiatric Institute and Clinic.

Dr. Fournier’s research focuses on identifying patient characteristics that are associated with differential response to treatments for depression, including placebo, antidepressant medications, and psychotherapy. In addition, his work investigates the neural and behavioral mechanisms through which those characteristics either facilitate or inhibit response to relevant treatments. As such, Dr. Fournier’s research bridges work in clinical interventions, mood disorders, personality, and neuroscience.

Ellen Frank, PhD

Positions

Professor of Psychiatry and Psychology, Department of Psychiatry, University of Pittsburgh School of Medicine
Director, Depression Prevention Program, Western Psychiatric Institute and Clinic, University of Pittsburgh Medical Center

Education & Training

PhD, 1979, University of Pittsburgh, Clinical Psychology

Ellen Frank is Distinguished Professor Emeritus of Psychiatry at the University of Pittsburgh School of Medicine and Chief Clinical Research Officer of HealthRhythms, Inc., a mobile technology company developing smartphone-based behavioral monitoring for clinical trials and digital intervention platforms.

For more than 35 years, Dr. Frank’s work focused on a better understanding of mood disorders and their treatment. Her 1990 study of maintenance therapies in recurrent unipolar depression is considered a classic in the field. She and her colleagues subsequently demonstrated the preventive efficacy of interpersonal and social rhythm therapy (IPSRT), a psychosocial intervention originally developed for adult outpatients with bipolar I disorder and subsequently modified for a broader range of mood disorders, age groups and treatment settings. Since transitioning to emeritus status, Dr. Frank has focused her attention on the development and testing of smartphone-based digital biomarkers and therapeutic platforms based on the social rhythm regulation conceptual model.

An expert on mood disorders and their treatment, Dr. Frank has published more than 475 peer-review papers, in addition to over 100 book chapters and books. In 1999, Dr. Frank was elected to the National Academy of Medicine.

Tina Goldstein, PhD

Positions

Associate Professor of Psychiatry and Psychology, University of Pittsburgh School of Medicine, Pittsburgh, PA

Education & Training

PhD, University of Colorado, Boulder, CO

Dr. Goldstein is an Associate Professor at University of Pittsburgh School of Medicine. Her research includes psychosocial treatments, pediatric bipolar disorder, suicidal and self-injurious behaviors. Dr. Goldstein's clinical interests include dialectical behavior therapy, cognitive behavior therapy, family-based therapies, pediatric mood disorders, and suicidal and self-injurious behaviors.

Andrea Goldstein-Piekarski, PhD

Positions

Assistant Professor (Research), Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine
Investigator, VISN21 Sierra-Pacific MIRECC at VA Palo Alto

Education & Training

PhD, University of California, Berkeley, Psychology/Neuroscience

Dr. Goldstein-Piekarski directs the Computational Psychiatry, Neuroscience, and Sleep Laboratory (CoPsyN Sleep Lab) as an Assistant Professor in the Department of Psychiatry and Behavioral Sciences at Stanford University School of Medicine and PI within the Sierra-Pacific Mental Illness Research, Education and Clinical Center (MIRECC) at the Palo Alto VA. She received her PhD in 2014 at the University of California, Berkeley where she studied the consequences of sleep on emotional brain function. She then completed a Postdoctoral fellowship at Stanford focusing on understanding the brain basis of anxiety and depression.

As the director of the CoPsyN Sleep Lab she is developing a translational, interdisciplinary research program that combines human neuroimaging, high-density EEG sleep recording, and computational modeling to understand the neural mechanisms through which sleep disruption contributes to affective disorders, particularly depression, across the lifespan. The ultimate goals of this research are to (1) develop mechanistically-informed interventions that directly target aspects of sleep and brain function to prevent and treat affective disorders and (2) identify novel biomarkers which can identify which individuals are most likely to experience improved mood following targeted sleep interventions.

This work is currently supported by The KLS Foundation, a R01 from National Institute of Mental Health, and a R61 from the National Institute of Mental Health.

Ian Gotlib, PhD

Positions

David Starr Jordan Professor, Department of Psychology, Stanford University
Director of the Stanford Neurodevelopment, Affect, and Psychopathology (SNAP) Laboratory, Stanford University

Education & Training

PhD, University of Waterloo, Clinical Psychology

Dr. Gotlib is the David Starr Jordan Professor, Director of the Stanford Neurodevelopment, Affect, and Psychopathology (SNAP) Laboratory, and a faculty member in the Neurosciences Graduate Program at Stanford University. From 2005-2010, Dr. Gotlib served as Senior Associate Dean for the Social Sciences, and he served as Chair of the Psychology Department at Stanford from 2012-2018.

In his research, Dr. Gotlib examines psychobiological factors that place individuals at increased risk for developing depression and engaging in suicidal behaviors, as well as processes that are protective in this context. More specifically, Dr. Gotlib examines neural, cognitive, social, endocrinological, and genetic factors in depressed individuals and applies findings from these investigations to the study of predictors of depression in children at risk for this disorder. In related projects, Dr. Gotlib is also examining the differential effects of early life stress on trajectories of neurodevelopment in boys and girls through puberty in an effort to explain the increased prevalence of depression and suicidal behaviors in girls in adolescence. Finally, Dr. Gotlib is extending this work to the study of brain function and structure, endocrine function, and behaviors in neonates and infants being raised in suboptimal environments.Dr. Gotlib’s research is supported largely by grants from the National Institutes of Health. He has also been funded by the National Health Research Development Program and the Medical Research Council of Canada, and leads an interdisciplinary team funded by PHIND at Stanford. Dr. Gotlib has received the Distinguished Investigator Award from the National Alliance for Research in Schizophrenia and Affective Disorders, the Joseph Zubin Award for lifetime research contributions to the understanding of psychopathology, the APA Award for Distinguished Scientific Contribution, the APS Distinguished Scientist Award, and a MERIT award from NIMH. He is a Fellow of the American Psychological Association, the Association for Psychological Science, and the American Psychopathological Association, and is Past President of the Society for Research in Psychopathology.

Dawn F. Ionescu, MD

Positions

Current Position

Senior Director and Clinical Leader, Neuroscience Experimental Medicine, Janssen

Previous Positions

Director, Neuroscience Clinical Development, JJIM
Assistant Professor, Harvard Medical School
Assistant in Psychiatry, Massachusetts General Hospital

Education & Training

B.A., History and Philosophy of Science, University of Pittsburgh, 2004
M.D., Penn State College of Medicine, 2009
Psychiatry Residency (PGY-1 through PGY-3), The George Washington University School of Medicine & Health Sciences, 2009-2012
Psychiatry Residency (PGY-4), National Institute of Mental Health, 2012-2013
Clinical Research Fellowship, National Institute of Mental Health, 2013-2014

Dr. Dawn F. Ionescu received a B.A. in the History & Philosophy of Science from the University of Pittsburgh, attended medical school at Penn State, and completed three years of a general psychiatry residency at The George Washington University. As a PGY-4 resident, she transferred to the NIMH's intramural training program. There, under the mentorship of Dr. Carlos Zarate in the Experimental Therapeutics and Pathophysiology Branch, she studied ketamine's antidepressant effects in patients with treatment resistant depression, with a focus on studying anxious depression. After she completed residency and a 1-year fellowship in clinical research at the NIMH, she took a faculty position at Massachusetts General Hospital/Harvard Medical School, where she was awarded grant funding through a KL2/CMeRIT Award, a K23 award from the NIMH, and a NARSAD Young Investigator Award to study ketamine's antidepressant and antisuicidal effects. She also collaborated with the MIT Media Lab on the development of wearable, noninvasive sensors for the diagnosis and prognosis of depression. For her experience in clinical research, she was selected as a member, and later, Chair, of the FDA's Psychopharmacologic Drugs Advisory Committee (PDAC). In 2017, she transitioned her career to industry to be a part of the esketamine development program at Johnson & Johnson Innovative Medicine (formally Janssen Pharmaceuticals), where she was part of the team that developed Spravato (esketamine) for patients with major depressive disorder with suicidal ideation. Based in La Jolla, CA, she is currently an Executive Medical Director in Neuroscience at Johnson & Johnson Innovative Medicine. She specifically works on a team that moves compounds from discovery to early clinical drug development, with a focus on phase 1 and 2 studies.

Ayana Jordan, MD, PhD

Positions

Barbara Wilson Associate Professor of Psychiatry, NYU Langone Health
Pillar Lead for Community Engagement in NYU Langone's Institute for Excellence in Health Equity
Associate Professor in the Department of Population Health, NYU Langone Health

Education & Training

MD/PhD, Albert Einstein College of Medicine of Yeshiva University (2011)
MS, Albert Einstein College of Medicine of Yeshiva University (2006)
BS, Hampton University (2001)

Dr. Jordan completed an MD, PhD program at Albert Einstein College of Medicine of Yeshiva University in NYC, where she became passionate about serving minority populations. She completed a general adult psychiatric residency at Yale University, where she served as Program-Wide Chief. During residency, Dr. Jordan became interested in treating patients with substance use disorders, given the intense stigma witnessed from other disciplines. Given her dedication to treating addiction, Dr. Jordan completed specialized addiction training at Yale, with a particular interest in using her research background to address clinical questions in the Black community. Currently, Dr. Jordan is the Barbara Wilson Associate Professor of Psychiatry at NYU Langone Health and also serves as the Pillar Lead for Community Engagement in NYU Langone's Institute for Excellence in Health Equity and as an associate professor in the Department of Population Health. She is committed to increasing access to addiction services within minority communities, both nationally and abroad. Dr. Jordan has done research in Sierra Leone, West Africa examining the link between, mental illness, substance use and stigma, and has served as an expert witness discussing these issues. In NY, Dr. Jordan is addressing health disparities by providing evidence-based treatment in the Black church for adults with alcohol use and other substance use disorders. Her work focuses on providing lifesaving treatment to people that need it most. She is also principal investigator of of the Imani Breakthrough Project and employing an evidence-based recovery program adapted for use in Black and Latinx churches. These projects aim to understand how to create an inclusive culture of wellness for minority communities from a public health perspective.

Jordan F. Karp, MD

Positions

Chair, Psychiatry, the University of Arizona Health Sciences, College of Medicine
Member of the Graduate Faculty, the University of Arizona Health Sciences, College of Medicine
Professor, Psychiatry

Education & Training

MD, 1998, University of Pittsburgh School of Medicine
Psychiatry Residency, 2002, Columbia Presbyterian/New York State Psychiatric Institute
Geriatric Psychiatry Fellowship, 2003, University of Pittsburgh Medical Center

Jordan Karp, MD, is the Department Chair, Professor of Psychiatry, and Medical Director for Behavioral Health Technology. He is an expert in the fields of geriatric psychiatry, depression treatment, and suicide prevention.

Prior to joining the University of Arizona, Dr. Karp served as a professor of psychiatry, anesthesiology, and clinical and translational science at the University of Pittsburgh School of Medicine, where he directed the Late-Life Depression Prevention and Treatment Research Program, served as Director of Medical Student Mental Health Services, and was program director for the geriatric psychiatry fellowship.

Dr. Karp has authored more than 140 peer reviewed publications and has been continuously funded by the National Institutes of Health (NIH), Patient Centered Outcomes Research Institute (PCORI), American Foundation for Suicide Prevention (AFSP), and the Brain and Behavior Research Foundation (BBRF) since 2006.

Corey Keller, MD, PhD

Faculty

Class of 2018

Stanford University

Dr. Keller is an Assistant Professor of Psychiatry and Behavioral Sciences at Stanford University and an Assistant Professor at the Veterans Affairs PaloAlto Health Care System (VAPAHCS). He is a member of Stanford Bio-X and the Wu Tsai Neurosciences Institute. Dr. Keller received his MD and PhD in neuroscience from the Medical Scientist Training Program at Albert Einstein College of Medicine. He completed his residency in psychiatry at Stanford University Medical Center focused on interventional psychiatry. Dr Keller has received several grants including the F31, T32, K23, DP5 Early Independence Award, SBIR, and R01 awards. He co-developed a fully automated non-invasive brain mapping technique used across industry and academia, and has run two clinical trials (NCT01829165 and NCT02843373) collecting over 1500 participants across ten clinical centers. Dr. Keller has extensive experience in the assessment and management of individuals with treatment-resistant depression. He has developed methodology for capturing the neurophysiology of human brain networks and the effect of stimulation through invasive and non-invasive electrophysiology.

The overarching goal of Dr. Keller’s Laboratory, the Laboratory for Personalized Neurotherapeutics (kellerlab.stanford.edu) is to improve brain stimulation treatment for neurological and psychiatric disease. His lab focuses on understanding the neural mechanisms of how brain stimulation technologies induce alter brain circuits in an effort to develop novel, personalized, and more effective brain stimulation treatments. His lab combines invasive and noninvasive human electrophysiology to answer these critical questions.

Carrie McAdams, MD, PhD

Positions

Associate Professor of Psychiatry, UT Southwestern Medical Center, Dallas TX

Dr. Carrie McAdams is an Associate Professor of Psychiatry at UT Southwestern Medical Center. Dr. McAdams’ research is focused on the relationship between cognition and brain function. Her graduate work at Baylor College of Medicine and postdoctoral fellowship at Harvard Medical School examined how neuronal signaling was altered by visual attention in macaques. With the development of functional magnetic resonance imaging (MRI), she became excited about the potential of this technique to examine how cognitive processes contribute to mental illness. Focusing on brain function in eating disorders, she has identified differences in the neural circuitry involved in social and self-perception and related these differences to illness and recovery in anorexia nervosa.

Her current research examines the connections between biological and psychological aspects of eating disorders using functional neuroimaging. She has focused on understanding the neurodevelopmental changes related to identity formation and social cognition. These constructs are closely related to long-term psychotherapeutic interventions in eating disorders.

Aoife O'Donovan, PhD

Positions

Associate Professor In Residence, Department of Psychiatry and Behavioral Sciences, UCSF
Research Psychologist, San Francisco Veterans Affairs Healthcare System

Education & Training

BA, University College Cork, Ireland
MPsychSc, National University of Ireland, Galway
PhD, University College Dublin, Ireland

Dr. O’Donovan is an Associate Professor in the Department of Psychiatry and Behavioral Sciences (DPBS) at the University of California, San Francisco, Research Psychologist at the San Francisco Veterans Affairs Healthcare System, and Director of the UCSF Trauma and Health Research on Immunity, Vitality, and Emotions (THRIVE) Laboratory. Her work focuses on uncovering mechanisms of stress-related ill health with a particular focus on inflammation as a mechanism of both mental and physical disorders following stress exposure. In prior work, she has demonstrated strong links of psychiatric disorders with risk for major chronic medical diseases; elevated inflammatory activity in association with psychiatric disorders and suicide ideation; links between elevated inflammation and alterations in brain structure, as well as accelerated biological aging in association with psychiatric disorders and psychological factors. Funded by the Department of Defense, the National Institute on Mental Health, and the UCSF Resource Allocation Program, she is currently running experimental studies to examine the impact of inflammation on the brain and psychiatric symptoms, randomized controlled trials of cognitive training and pharmacological interventions for PTSD, and studied focused on uncovering the impact of the COVID-19 pandemic in people with and without PTSD.

Michael J. Ostacher, MD, MPH

Positions

Professor - University medical Line, Psychiatry and Behavioral Sciences, Stanford University

Education & Training

MD, Vanderbilt University School of Medicine MPH, Harvard University School of Public Health, Health Care Management

Dr. Ostacher is Professor of Psychiatry and Behavioral Sciences. He is the Site Director for the Addiction Medicine Fellowship at the VA Palo Alto Health Care System, where he also serves as the Medical Director of the Pharmacology of Addiction Recovery Clinic, the Director of the Bipolar and Depression Research Program and the Director of Advanced Fellowship Training in Mental Illness Research and Treatment for MDs for the VISN 21 MIRECC, and the Site Director at the VA Palo Alto for Advanced Fellowship Training for Stanford. A graduate of Vanderbilt University School of Medicine, the Harvard School of Public Health, and Harvard Medical School, he completed his training at The Cambridge Health Alliance at Harvard Medical School in Adult Psychiatry, Public Psychiatry, and Geriatric Psychiatry, and is currently board certified in Psychiatry, Addiction Psychiatry, and Addiction Medicine. He is the Digital Content Editor for the journal Evidence-Based Mental Health and is on the editorial boards of Bipolar Disorders, the International Journal of Bipolar Disorders, the Journal of Clinical Psychiatry, Current Psychiatry, and Psychiatric Annals. His current research includes roles as Site Investigator for VA-BRAVE, multicenter, randomized trial comparing long-acting injectable buprenorphine to sublingual buprenorphine/naloxone, and as a Co-investigator for PRIME-VA, a 21-site study of pharmacogenomics in the treatment of major depressive disorder. With funding from NIDA, he studies, along with Jaimee Heffner, Ph.D. at the Fred Hutchinson Cancer Research Center in Seattle, smoking cessation in people with bipolar disorder using a novel online psychotherapy derived from Acceptance and Commitment Therapy. His primary research interest is in large clinical trials mental health and addiction, and the implementation of evidence-based mental health practices.

Mercedes Perez-Rodriguez, MD, PhD

Positions

Assistant Professor of Psychiatry, Icahn School of Medicine at Mount Sinai
Director, Medical Student Clerkship
Associate Director, Medical Student Education
Assistant Training Director for Research
Medical Director and Director of Research Training, Psychosis Research Program (Critical Connections)
Social Cognition Section Co-Chief, Center for Affective Neuroscience

Dr. Perez’s work, funded by the NIH, the CDC, the Brain and Behavior Research Foundation (NARSAD), the VA MIRECC, and industry collaborations, aims to elucidate the neurobiological underpinnings of risk and resilience to psychosis spectrum and trauma-related disorders, with a focus on cognition and social cognition. The goal of Dr. Perez’s lab is to develop and test new treatments for psychosis spectrum and trauma-related disorders informed by the neurobiology of the cognitive and social cognitive impairments commonly present in these disorders.

Dr. Perez has authored or co-authored over 100 publications, including more than 70 papers in in peer-reviewed journals and 15 book chapters.

As Assistant Training Director for Research and Director of the Medical Student Clerkship, Dr. Perez plays a key role in educating and mentoring medical students and residents at Mount Sinai. She co-directs the NIMH R25-supported Combined Psychiatry Residency and PhD Program and the Physician-Scientists Psychiatry Residency Research Track at Mount Sinai (https://icahn.mssm.edu/education/residencies-fellowships/list/msh-psychiatry-residency/research-tracks).

Her commitment to training the next generation of physician-scientists has been recognized with her appointment to the AAMC Committee on Creating a Physician-Scientist Training and Career Development Home. Dr. Perez is a Friedman Brain Institute Research Scholar and a Faculty Scholar at Mount Sinai's Center for Multicultural and Community Affairs, which focuses on fostering diversity in our clinical and research workforce.

Dr. Perez is a Fellow Member of the American Psychiatric Association, a Member of the American College of Psychiatrists, an Associate Member of the American College of Neuropsychopharmacology (ACNP), and an elected member of the board of directors of the American Society of Hispanic Psychiatry.

Noah S. Philip, MD

Positions

Professor of Psychiatry and Human Behavior, Alpert Medical School of Brown University
Founding Section Chief of Psychiatric Neuromodulation, Providence VA Medical Center
Lead for Mental Health Reseawrch, VA RR&D Center for Neurorestoration and Neurotechnology

Education & Training

MD with Distinction in the Study of Biomedical Ethics, Alpha Omega Alpha, Albany Medical College, 2005
T32 Research Fellow, Brown University, 2009
Neuromodulation Fellow, Butler Hospital, 2011

Noah S. Philip MD is a Professor of Psychiatry and Human Behavior at the Alpert Medical School of Brown University. He is the founding Section Chief of Psychiatric Neuromodulation at VA Providence, and is Lead for Mental Health Research at the VA RR&D Center for Neurorestoration and Neurotechnology. Dr. Philip’s laboratory uses cutting edge technology to understand and treat posttraumatic stress disorder, major depression, suicidality, and other serious psychiatric diseases. He uses noninvasive brain stimulation and functional neuroimaging towards these goals, with methods that integrate electromagnetic stimulation (e.g., repetitive TMS, theta burst TMS, transcranial direct current stimulation, etc.), functional connectivity, psychotherapy, and virtual reality. Dr. Philip's research has been featured in the American Journal of Psychiatry, Biological Psychiatry, and in the National Neuroscience Curriculum Initiative. Dr. Philip is supported by brain stimulation and neuroimaging grants through the Veterans Administration, National Institutes of Drug Abuse, Department of Defense, and through industry collaborations. He is active in the American College of Neuropsychopharmacology, Society for Biological Psychiatry, and the National Neuroscience Curriculum Initiative (tDCS+Virtual Reality for PTSD). In June 2021, he received a cooperative study award from NIMH to perform first-in-human studies investigatingMRI-guided low intensity focused ultrasound for depression and anxiety. He plays a significant mentoring role at Brown University where he is Associate Director of the NIMH R25-supported psychiatry resident research program.

Carolyn Rodriguez, MD, PhD

Positions

Professor, Psychiatry and Behavioral Sciences, Stanford University School of Medicine
Associate Dean for Academic Affairs, Stanford University School of Medicine
Director, Translational Therapeutics/Rodriguez Lab, Stanford University
Director, Translational OCD Research Program, Stanford University
Director, Stanford Hoarding Disorders Research Program, Stanford University

Education & Training

MD, Harvard Medical School, Medicine
PhD, Harvard Medical School, Neuroscience, Genetics

Dr. Carolyn Rodriguez is Associate Dean for Academic Affairs, Stanford University School of Medicine and a Consultation-Liaison Psychiatrist at the Palo Alto Veterans Affairs. As the Director of the Translational Therapeutics Lab and Professor in the Department of Psychiatry and Behavioral Sciences, Dr. Rodriguez leads studies investigating the brain basis of severe mental disorders. Her landmark clinical trials pioneer rapid-acting treatments for illnesses including Obsessive-Compulsive Disorder (OCD) and related disorders. Her NIH-, foundation-, and donor-funded mechanistic and clinical efficacy studies span targeted glutamatergic and opioid pathway pharmacotherapy, noninvasive brain stimulation, psychotherapy and suicide prevention. She is co-author of “Hoarding Disorder: A Comprehensive Clinical Guide,” published August 2022 by APA Publishing.

Dr. Rodriguez also serves as Deputy Editor of The American Journal of Psychiatry, member of the Research Council of the American Psychiatric Association, member of Brain & Behavior Research Foundation Scientific Council, member of the American Foundation for Suicide Prevention Advisory Group, and Scientific and Clinical Advisory Board member of the International OCD Foundation. She has won several national awards, including the Presidential Early Career Award for Scientists and Engineers (PECASE). The PECASE recognizes investigators who are pursuing bold and innovative projects and is considered one of the highest honors in scientific research. Carolyn presented her research at the World Economic Forum in Davos and Fortune Brainstorm Health 2022 and her work has been highlighted by organizations including NPR, PBS, New York Times, ABC News, NBC News, Newsweek, Fortune, and Time.com. She contributes articles to Harvard Business Review and Huffington Post to share scientific findings with the public.

Carolyn received her B.S. in Computer Science from Harvard University, followed by an M.D. from Harvard Medical School-M.I.T. and a Ph.D. in Neuroscience and Genetics from Harvard Medical School. Born in San Juan, Puerto Rico, she now lives with her husband and three children in Palo Alto.

Joshua Roffman, MD

Positions

Associate Professor, Department of Psychiatry, Harvard Medical School
Co-Director, Mass General Neuroscience
Co-Director, MGH Division of Psychiatric Neuroimaging, Massachusetts General Hospital
Editor in Chief, Harvard Review of Psychiatry

Education & Training

MMSc, 2010, Harvard Medical School, Clinical Investigation
MD, 2001, University of Maryland School of Medicine, Medicine

Dr. Roffman is a psychiatrist and neuroscientist who focuses on biological underpinnings of serious mental illlness (SMI). A CDI alumnus (class of 2004), Dr. Roffman was supported by two five-year career development awards, including a K23 from NIMH, followed by a BRAINS R01 from NIMH and an MQ Fellows award. Dr. Roffman currently directs the Brain Genomics Lab at MGH, which seeks to identify early-life protective factors against SMI risk through developmental cohort studies, multi-modal brain imaging, and genomics. Dr. Roffman co-directs Mass General Neuroscience, a hospital-wide initiative that fules innovative treatment and prevention strategies through translational research. He also co-directs the MGH Division of Psychiatric Neuroimaging, is a founding director of the Translational Neuroscience Training for Clinicians T32 fellowship, co-directs the Introduction to Psychopathology course for second-year medical students in HST, and serves as Editor in Chief of the Harvard Review of Psychiatry. His research centers on identifying prenatal/early life protective factors that confer resilience against SMI risk in childhood and adolescence, bridging cohort studies with brain imaging, genomics, and other translational neuroscience approaches. His mentees have gone on to grad school in genetics, psychology, and neuroscience; MD and MD-PhD programs; and psychiatry faculty positions.

Andrea Schneider, JD

Positions

Professor of Law and Director of the Kuhn Program Conflict Resolution, Yeshiva Uiversity Cardazo Law School, New York, NY

Education & Training

JD, Harvard Law School

Andrea Kupfer Schneider is a Professor of Law and has taught Dispute Resolution, Negotiation, Ethics, and International Conflict Resolution for 25 years. She is the inaugural director of the Institute for Women’s Leadership at Marquette University and also served as the Director of the nationally ranked Dispute Resolution Program at Marquette University Law School until July 2022, when she joined Cardozo Law School in New York as the director of the Kukin Program for Conflict Resolution. Professor Schneider is the author or co-author of numerous books in the field including leading textbooks on dispute resolution, negotiation, mediation, and dispute resolution in the criminal context. She has also edited multiple volumes focusing on interdisciplinary approaches to negotiation including Negotiation Essentials for Lawyers and The Negotiator’s Desk Reference both co-edited with Chris Honeyman. She has published articles on negotiation, ethics, pedagogy, gender and international conflict. Professor Schneider was named 2009 Woman of the Year by the Wisconsin Law Journal and, in 2016, gave her first TEDx talk entitled Women Don’t Negotiate and Other Similar Nonsense. She was named the 2017 recipient of the ABA Section of Dispute Resolution Award for Outstanding Scholarly Work. She received her A.B. cum laude from Princeton University and her J.D. cum laude from Harvard Law School.

Holly Swartz, MD

Positions

Professor of Psychiatry, Department of Psychiatry, University of Pittsburgh School of Medicine, and Western Psychiatric Institute and Clinic, Pittsburgh, PA
Director, Center for Advanced Psychotherapy, UPMC Western Psychiatry Hospital
Medical Director, Depression and Manic Depression Prevention Program, UPMC Western Psychiatric Hospital

Education & Training

MD, 1990, Albert Einstein College of Medicine, Bronx, NY

Dr. Swartz's research focuses on optimizing psychosocial treatments for mood disorders. She is currently testing the impact of maternal depression treatment on offspring also receiving treatment and the role of psychotherapy in the management of bipolar II disorder. She is also interested in the process of moving efficacious psychosocial interventions to routine practice settings.

Holly Swartz, MD

Positions

Associate Professor of Psychiatry and Biostatistics, University of Pittsburgh, Pittsburgh PA

Education & Training

PhD, Biostatistics, University of Pittsburgh

Dr. Wallace's research interests broadly revolve around developing and applying statistical methods to improve personalized medicine and include moderators in randomized clinical trials, decision trees, and clustering. With support from a K01 Career Development Award from National Institute of Mental Health, Dr. Wallace is currently developing clustering methods that incorporate data captured across multiple units of analysis (e.g., self-report, behavior, physiology). She applies these methods to data sets that cut across clinical diagnoses in order to reveal subgroups with different expressions of signs and symptoms.

Leanne Williams, PhD

Positions

Professor of Psychiatry & Behavioral Sciences, Stanford University
Director of the PanLab for Personalized and Translational Neuroscience, Stanford and Palo Alto MIRECC VISN21
Director of PTSD Education, VA Palo Alto MIRECC VISN21
Honorary Professor, Sydney Medical School

Education & Training

PhD, 1996, Oxford University

Dr. Williams's research program is motivated by the need for a new model of mental disorder, one that integrates two complex systems: human brain function and human behavior. She uses multiple brain imaging techniques to develop brain-based models for classifying disorders that cut across multiple diagnostic categories. Her research program combines basic and clinically applicable neuroscience. Basic neuroscience investigations using MRI, EEG, imaging genetics, and behavioral measures are aimed at understanding neurodevelopment context of mental disorder and its treatment across the lifespan. In parallel, she pursues new designs for real world "practical" trials that are coupled with measures of brain circuits and genetics to identify biomarkers for prediction which treatments are most effective for each person. These approaches rely on harnessing modern computational methods to manage big datasets and address data-driven questions that cut across diagnostic categories. The program is interdisciplinary and seeks to advance personalized neuroscience for mental disorder. Dr. Williams's lab has a particular focus on large-scale neural circuits and emotional function. Given the immediate public need, the most recent studies focus on depression and anxiety.

Nolan Williams, MD

Positions

Assistant Professor - Med Center Line, Psychiatry and Behavioral Sciences - Stanford University
Director, Stanford Interventional Psychiatry Clinical Research
Director, Stanford Brain Stimulation Laboratory

Education & Training

MD, Medical University of South Carolina, Medicine (2008)

Dr. Williams is an Assistant Professor within the Department of Psychiatry and Behavioral Sciences and the Director of the Stanford Brain Stimulation Lab. Dr. Williams has a broad background in neuropsychiatry, completing residencies in both neurology and psychiatry. In addition, he has specific training and clinical expertise in the development of brain stimulation methodologies under Mark George, MD. Themes of his work include (a) examining the use of spaced learning theory in the application of neurostimulation techniques, (b) development and mechanistic understanding of rapid-acting antidepressants, and (c) identifying objective biomarkers that predict neuromodulation responses in treatment-resistant neuropsychiatric conditions. He has published papers in high impact peer-reviewed journals including Brain, American Journal of Psychiatry, and the Proceedings of the National Academy of Science. He has also contributed to two reviews related to novel therapeutics for neuropsychiatric conditions that have been published in the Journal of Clinical Investigation and Current Opinion in Neurobiology, which are both highly cited. Results from his studies have gained widespread attention in journals such as Science and New England Journal of Medicine Journal Watch as well as in the popular press and have been featured in various news sources including Time, Smithsonian, and Newsweek. Dr. Williams received an NIH R-series grant within two years of completing his residencies as well as two NARSAD Young Investigator Awards in 2016 and 2018 along with the 2019 Gerald R. Klerman Award. He started the Stanford Brain Stimulation Lab in 2015. He has received several merit-based travel awards to attend and present at the annual meetings for American College of Neuropharmacology, Society of Biological Psychiatry, the American Academy of Neurology and the American Neuropsychiatric Association.

Daniel Wolf, MD, PhD

Positions

Associate Professor, Department of Psychiatry, University of Pennsylvania School of Medicine
Attending Psychiatrist, Department of Psychiatry, Hospital of the University of Pennsylvania
Attending Psychiatrist, Department of Psychiatry, Pennsylvania Hospital

Education & Training

PhD, Yale University School of Medicine, Neuroscience
MD, Yale University School of Medicine

Dr. Wolf is an Associate Professor of Psychiatry with tenure at the University of Pennsylvania School of Medicine. His research focuses on the neural mechanisms of emotional and motivational abnormalities across psychiatric disorders particularly psychotic disorders and in youth at risk for psychosis. He employs functional neuroimaging (fMRI), behavioral neuroeconomic paradigms, and pharmacological challenges in his work. He has been funded by NIMH via a K23 Career Development Award, a completed R01 and an ongoing R01, and has also received a number of smaller foundation awards, including a NARSAD Young Investigator Award, and the APIRE-AstraZeneca Young Minds in Psychiatry Award. He has served multiple times as an ad hoc member of NIMH review panels. He also works as an outpatient attending psychiatrist, teaching residents and medical students how to provide longitudinal care to individuals with psychotic disorders. He also actively mentors postdocs, graduate students, and junior faculty at the University of Pennsylvania, providing advice and support in their efforts to publish papers and apply for grants, and is the Associate Director of a T32 program and Director of the Penn Clinical Neurosciences Training Program. Dr. Wolf grew up in Los Angeles, completed undergraduate work at Harvard College, MD-PhD training at Yale University, psychiatry residency at MGH-McLean, and neuropsychiatry fellowship at UPenn. Outside of work he focuses on spending time with his wife and three children.

Josh Woolley, MD, PhD

Positions

Associate Professory, Psychiatry, UCSF Weill Institute for Neurosciences

Education & Training

MD, 2007, University of California, San Francisco
PhD, 2005, University of California, San Francisco

Dr. Woolley has been studying the underpinnings of social deficits in schizophrenia and has examined how oxytocin might be a useful treatment for these social deficits. People with schizophrenia often have functionally significant social cognitive deficits, and there are currently no available pharmacological treatments that target these deficits. In healthy individuals, the natural hormone oxytocin has been shown to increase social abilities such as understanding emotions and trusting people. People with schizophrenia can have difficulties with social relationships, which can impact interactions with others and community participation. Dr. Woolley believes that oxytocin may help with many of these difficulties, so a major focus of his research laboratory has been to examine whether supplementary oxytocin can increase social cognition in people with schizophrenia.

Directors

Erika E. Forbes, PhD

David J. Kupfer, MD

Alan F. Schatzberg, MD

Faculty

Rebecca Ashare, PhD

Melissa Brotman, PhD

Enrico Castillo, MD, MSHPM

Jay Fournier, PhD

Ellen Frank, PhD

Tina Goldstein, PhD

Andrea Goldstein-Piekarski, PhD

Ian Gotlib, PhD

Dawn Ionescu, MD

Ayana Jordan, MD, PhD

Jordan F. Karp, MD

Corey Keller, MD, PhD

Carrie McAdams, MD, PhD

Aoife O'Donovan, PhD

Michael J. Ostacher, MD, MPH

Mercedes Perez-Rodriguez, MD, PhD

Noah S. Philip, MD

Carolyn Rodriguez, MD, PhD

Joshua Roffman, MD

Andrea Schneider, JD

Holly Swartz, MD

Meredith Wallace, PhD

Leanne Williams, PhD

Nolan Williams, MD

Daniel Wolf, MD, PhD

Josh Woolley, MD, PhD

Erika E. Forbes, PhD

Positions

Education & Training

David J. Kupfer, MD

Positions

Education & Training

Alan F. Schatzberg, MD

Positions

Education & Training

Rebecca Ashare, PhD

Position

Education & Training

Melissa Brotman, PhD

Positions

Enrico Castillo, MD, MSHPM

Positions

Education & Training

Jay Fournier, PhD

Positions

Education & Training

Ellen Frank, PhD

Positions

Education & Training

Tina Goldstein, PhD

Positions

Education & Training

Andrea Goldstein-Piekarski, PhD

Positions

Education & Training

Ian Gotlib, PhD

Positions

Education & Training

Dawn F. Ionescu, MD

Positions

Education & Training

Ayana Jordan, MD, PhD

Positions

Education & Training

Jordan F. Karp, MD

Positions

Education & Training

Corey Keller, MD, PhD

Carrie McAdams, MD, PhD

Positions

Aoife O'Donovan, PhD

Positions

Education & Training

Michael J. Ostacher, MD, MPH